Zobrazeno 1 - 10
of 54
pro vyhledávání: '"63"'
Autor:
David Luke, Vincent Young, Michael Leotsinidis, Eillish McGovern, Ann Maree Hughes, Harry Parissis
Publikováno v:
Asian Cardiovascular and Thoracic Annals. 17:175-182
To compare the outcome of sleeve resection or complex sleeve resection versus (Vs) pneumonectomy for lung cancer in a single unit. Between 1998 and 2006, 664 lung resections were carried out. There were 129 (19.4%) pneumonectomies and 79 (11.9%) slee
Autor:
Josephine Feliciano, Michael Lim, Pavan P. Shah, Jarushka Naidoo, Christopher M. Jackson, Kristen A. Marrone, Lawrence Kleinberg, Siddhartha Srivastava, Julie R. Brahmer, John Choi, Patrick M. Forde, Kristin J. Redmond, Jennifer L. Franke, David S. Ettinger, Benjamin Levy, Ravi Medikonda
Publikováno v:
Journal of Neurosurgery. 136:56-66
OBJECTIVE Non–small cell lung cancer (NSCLC) is the most common primary tumor to develop brain metastasis. Prognostic markers are needed to better determine survival after neurosurgical resection of intracranial disease. Given the importance of mut
Publikováno v:
Anti-Cancer Drugs. 32:882-885
Erlotinib is a tyrosine kinase inhibitor that inhibits epidermal growth factor receptor. It is being used for metastatic non-small cell lung cancer patients (NSCLC). Repurposing noncancer drugs for cancer treatment is a current issue and it has many
Publikováno v:
The Journal of Thoracic and Cardiovascular Surgery. 114:347-353
Objectives: To comparatively evaluate lobectomy and limited resection for T1 N0 M0 non-small-cell lung cancer, we reviewed case series with concurrent nonrandomized controls. Methods: Limited resection with curative intent was performed for 63 patien
Autor:
Veljka Ivcevic, Merica Glavina Durdov, Antonia Pavlovic, Vesna Čapkun, Violeta Soljic, Mari Peric, Renata Beljan Perak
Publikováno v:
Diagnostic Pathology
Diagnostic Pathology, Vol 7, Iss 1, p 165 (2012)
Diagnostic Pathology, Vol 7, Iss 1, p 165 (2012)
Background Lung cancer most often presents as an inoperable tumour and the diagnosis is usually performed on a small biopsy/cytology specimen. In the group of non small cell lung cancer - not otherwise specified, adenocarcinoma phenotype can be deter
Autor:
Yong-Bing Xiang, X. Fu, Hao Qian, Da-ren Shi, Xiong-Zeng Zhu, Liang-Zhong Xiu, Li-Juan Wang, Hong-Fen Lu, Sen Zhao, Guo Liang Jiang
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 23(2)
Background : The outcome of treatment in non-small cell lung cancer (NSCLC) remains poor. One of the reasons is that in many patients its biological behavior does not follow a definite pattern, and can not be accurately predicted prior to treatment.
Autor:
Masaya Nakamura, Hiroyuki Ishikawa, Seijiro Sato, Tatsuya Goto, Masanori Tsuchida, Yuki Shimizu, Terumoto Koike
Publikováno v:
BMC Pulmonary Medicine, Vol 19, Iss 1, Pp 1-10 (2019)
BMC Pulmonary Medicine
BMC Pulmonary Medicine
Background The presence of emphysema on computed tomography (CT) is associated with an increased frequency of lung cancer, but the postoperative outcomes of patients with pulmonary emphysema are not well known. The objective of this study was to inve
Autor:
Abdullah Alsuhaibani, Faisal ALzorkany, Abdullah Alkafi, Ahmed Elashwah, Camelia Constantinescus
Publikováno v:
Journal of Gastrointestinal Cancer. 50:879-887
We retrospectively evaluate local control rate at 6 months and 1 year in oligometastatic cancer patients treated with SBRT using CyberKnife. Total of 21 patients with 24 treatment sites from February 2014 till June 2017 who were treated with SBRT in
Autor:
Keyur P. Patel, Sinchita Roy-Chowdhuri, John V. Heymach, Roberto Ruiz-Cordero, L. Jeffrey Medeiros, Roland Bassett, Mark J. Routbort, Waree Rinsurongkawong, Ferdinandos Skoulidis, Jianjun Zhang, Abha Khanna, Zhenya Tang, Junsheng Ma, Emily Roarty, Ming Guo, Rajyalakshmi Luthra, Genevieve Lyons
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-11 (2020)
BMC Cancer
BMC Cancer, vol 20, iss 1
BMC Cancer
BMC Cancer, vol 20, iss 1
Background Gene expression profiling has consistently identified three molecular subtypes of lung adenocarcinoma that have prognostic implications. To facilitate stratification of patients with this disease into similar molecular subtypes, we develop
Autor:
Juan Lin, Adel Chergui, Sanjay Goel, Haiying Cheng, Vineeth Sukrithan, Alexander Barbaro, Brian Ko
Publikováno v:
Am J Clin Oncol
OBJECTIVES Bevacizumab with chemotherapy improved overall survival (OS) in the E4599 trial in metastatic nonsquamous non-small cell lung cancer (NS-NSCLC). A meta-analysis demonstrated an OS benefit with bevacizumab only in a subset of nonwhite patie